Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Goodwill & Intangibles (2016 - 2025)

IGC Pharma has reported Goodwill & Intangibles over the past 15 years, most recently at $566000.0 for Q3 2025.

  • Quarterly Goodwill & Intangibles fell 1.91% to $566000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $566000.0 through Sep 2025, down 1.91% year-over-year, with the annual reading at $1.5 million for FY2025, 116.69% up from the prior year.
  • Goodwill & Intangibles was $566000.0 for Q3 2025 at IGC Pharma, down from $1.7 million in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $1.7 million in Q2 2025 and troughed at $181000.0 in Q1 2021.
  • The 5-year median for Goodwill & Intangibles is $566000.0 (2025), against an average of $610000.0.
  • Year-over-year, Goodwill & Intangibles decreased 28.17% in 2021 and then skyrocketed 145.83% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $426000.0 in 2021, then grew by 28.17% to $546000.0 in 2022, then rose by 5.31% to $575000.0 in 2023, then decreased by 0.7% to $571000.0 in 2024, then dropped by 0.88% to $566000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Goodwill & Intangibles are $566000.0 (Q3 2025), $1.7 million (Q2 2025), and $1.5 million (Q1 2025).